Colorectal hepatic metastasis - current therapeutic approach

Skye C. Mayo, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Colorectal cancer remains one of the most common cancers in the developed world, and metastasis to the liver accounts for the greatest proportion of morbidity and mortality from the disease after resection of the primary cancer. With improved screening and adjuvant therapy, the survival of patients has increased substantially over the last decade. However, patients with metastatic disease often have limited survival. Hepatic metastasis is one of the most frequent sites of metastatic disease. In fact, between 35 and 55% of patients with colorectal cancer will develop hepatic metastasis sometime during the course of their disease. Patients who are able to undergo complete resection of their hepatic metastases have the best chance of long-term survival. The goal of hepatic resection is to achieve complete resection of all metastases with microscopically negative surgical margins while preserving sufficient hepatic parenchyma. Survival following hepatic resection of colorectal metastasis now approaches 35-50%; however, approximately 65% of patients will have a recurrence at five years. Increasingly, chemotherapeutic agents are being offered in the pre-operative setting prior to surgery. At the time of operation, patients with extensive hepatic disease can sometimes be offered ablative therapies combined with resection or staged approaches. Modern management of hepatic colorectal metastasis necessitates a multidisciplinary approach to effectively treat these patients and increase the number of patients who will benefit from resection.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalEuropean Gastroenterology and Hepatology Review
Volume7
Issue number1
StatePublished - 2011

Fingerprint

Neoplasm Metastasis
Liver
Therapeutics
Survival
Colorectal Neoplasms
Neoplasms
Morbidity
Recurrence
Mortality

Keywords

  • Chemotherapy
  • Colorectal metastases
  • Hepatic resection
  • Liver
  • Radiofrequency ablation
  • Surgery

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Colorectal hepatic metastasis - current therapeutic approach. / Mayo, Skye C.; Pawlik, Timothy M.

In: European Gastroenterology and Hepatology Review, Vol. 7, No. 1, 2011, p. 54-60.

Research output: Contribution to journalArticle

Mayo, Skye C. ; Pawlik, Timothy M. / Colorectal hepatic metastasis - current therapeutic approach. In: European Gastroenterology and Hepatology Review. 2011 ; Vol. 7, No. 1. pp. 54-60.
@article{083586749ac241128808d6c846cb036b,
title = "Colorectal hepatic metastasis - current therapeutic approach",
abstract = "Colorectal cancer remains one of the most common cancers in the developed world, and metastasis to the liver accounts for the greatest proportion of morbidity and mortality from the disease after resection of the primary cancer. With improved screening and adjuvant therapy, the survival of patients has increased substantially over the last decade. However, patients with metastatic disease often have limited survival. Hepatic metastasis is one of the most frequent sites of metastatic disease. In fact, between 35 and 55{\%} of patients with colorectal cancer will develop hepatic metastasis sometime during the course of their disease. Patients who are able to undergo complete resection of their hepatic metastases have the best chance of long-term survival. The goal of hepatic resection is to achieve complete resection of all metastases with microscopically negative surgical margins while preserving sufficient hepatic parenchyma. Survival following hepatic resection of colorectal metastasis now approaches 35-50{\%}; however, approximately 65{\%} of patients will have a recurrence at five years. Increasingly, chemotherapeutic agents are being offered in the pre-operative setting prior to surgery. At the time of operation, patients with extensive hepatic disease can sometimes be offered ablative therapies combined with resection or staged approaches. Modern management of hepatic colorectal metastasis necessitates a multidisciplinary approach to effectively treat these patients and increase the number of patients who will benefit from resection.",
keywords = "Chemotherapy, Colorectal metastases, Hepatic resection, Liver, Radiofrequency ablation, Surgery",
author = "Mayo, {Skye C.} and Pawlik, {Timothy M.}",
year = "2011",
language = "English (US)",
volume = "7",
pages = "54--60",
journal = "European Gastroenterology and Hepatology Review",
issn = "1758-3799",
publisher = "Touch Briefings",
number = "1",

}

TY - JOUR

T1 - Colorectal hepatic metastasis - current therapeutic approach

AU - Mayo, Skye C.

AU - Pawlik, Timothy M.

PY - 2011

Y1 - 2011

N2 - Colorectal cancer remains one of the most common cancers in the developed world, and metastasis to the liver accounts for the greatest proportion of morbidity and mortality from the disease after resection of the primary cancer. With improved screening and adjuvant therapy, the survival of patients has increased substantially over the last decade. However, patients with metastatic disease often have limited survival. Hepatic metastasis is one of the most frequent sites of metastatic disease. In fact, between 35 and 55% of patients with colorectal cancer will develop hepatic metastasis sometime during the course of their disease. Patients who are able to undergo complete resection of their hepatic metastases have the best chance of long-term survival. The goal of hepatic resection is to achieve complete resection of all metastases with microscopically negative surgical margins while preserving sufficient hepatic parenchyma. Survival following hepatic resection of colorectal metastasis now approaches 35-50%; however, approximately 65% of patients will have a recurrence at five years. Increasingly, chemotherapeutic agents are being offered in the pre-operative setting prior to surgery. At the time of operation, patients with extensive hepatic disease can sometimes be offered ablative therapies combined with resection or staged approaches. Modern management of hepatic colorectal metastasis necessitates a multidisciplinary approach to effectively treat these patients and increase the number of patients who will benefit from resection.

AB - Colorectal cancer remains one of the most common cancers in the developed world, and metastasis to the liver accounts for the greatest proportion of morbidity and mortality from the disease after resection of the primary cancer. With improved screening and adjuvant therapy, the survival of patients has increased substantially over the last decade. However, patients with metastatic disease often have limited survival. Hepatic metastasis is one of the most frequent sites of metastatic disease. In fact, between 35 and 55% of patients with colorectal cancer will develop hepatic metastasis sometime during the course of their disease. Patients who are able to undergo complete resection of their hepatic metastases have the best chance of long-term survival. The goal of hepatic resection is to achieve complete resection of all metastases with microscopically negative surgical margins while preserving sufficient hepatic parenchyma. Survival following hepatic resection of colorectal metastasis now approaches 35-50%; however, approximately 65% of patients will have a recurrence at five years. Increasingly, chemotherapeutic agents are being offered in the pre-operative setting prior to surgery. At the time of operation, patients with extensive hepatic disease can sometimes be offered ablative therapies combined with resection or staged approaches. Modern management of hepatic colorectal metastasis necessitates a multidisciplinary approach to effectively treat these patients and increase the number of patients who will benefit from resection.

KW - Chemotherapy

KW - Colorectal metastases

KW - Hepatic resection

KW - Liver

KW - Radiofrequency ablation

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=79954589265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954589265&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79954589265

VL - 7

SP - 54

EP - 60

JO - European Gastroenterology and Hepatology Review

JF - European Gastroenterology and Hepatology Review

SN - 1758-3799

IS - 1

ER -